Degarelix and Relugolix Adverse Event Reports from FAERS, 2009-2024

Adverse event reports for two prostate cancer drugs were analyzed using the FDA Adverse Event Reporting System (FAERS). The dataset includes 3,357 reports for Degarelix and 4,075 reports for Relugolix from Q1 2009 through Q2 2024. The supplementary material was authored by figshare admin karger and published under a CC-BY-4.0 license.

Use Cases

• Signal detection for drug safety based on reported adverse events
• Comparative analysis of adverse event profiles between Degarelix and Relugolix
• Identification of rare adverse events not included in drug labeling
• Post-marketing safety monitoring for prostate cancer treatments

Strengths

• Contains 3,357 adverse event reports for Degarelix
• Contains 4,075 adverse event reports for Relugolix
• Analysis employs multiple signal detection methods (ROR, PRR, BCPNN, EBGM)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect reporting bias inherent to the FAERS database

Provenance

Source

FDA Adverse Event Reporting System (FAERS)

Collection Method

Analysis of adverse event reports retrieved from the FAERS database

Time Range

Q1 2009 through Q2 2024

Freshness

Last updated 2026-04-17 05:55:10; freshness should be verified